Log In
BCIQ
Print this Print this
 

Pirfenex, pirfenidone (Esbriet, Pirespa) (RG6062, S-7701)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSmall molecule inhibitor of proinflammatory cytokines and pro-fibrotic cytokines that targets p38 mitogen-activated protein kinase (p38 MAPK; MAPK14)
Molecular Target Tumor necrosis factor (TNF) alpha ; Transforming growth factor (TGF) beta 1 (TGFB1)
Mechanism of ActionMAP kinase (p38) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$8,300.0M

$8,300.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/29/2014

$8,300.0M

$8,300.0M

0

07/25/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today